Company intelligence / Profile preview
SoftOx Solutions
Oslo, Norwaysoft-ox.com ↗
- Ownership
- Private
- Employees
- ~7
- Development stage
- Other
01
Overview
SoftOx Solutions has developed a patent-protected, non-toxic antimicrobial technology targeting bacteria, fungi, viruses—including resistant strains—across multiple product lines. Clinical results indicate strong efficacy against biofilms and pathogens with good tolerability. The inhalation solution for respiratory tract infections has reached Phase II trials; wound care solutions have demonstrated infection removal in chronic wounds in clinical studies. Disinfectant products are available commercially or close to market launch
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small moleculeDevice
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
University of CopenhagenSkåne County universities (Sweden)Excite International Canada
Beyond the preview
Go deeper on SoftOx Solutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SoftOx Solutions.